Cubist gets fast-track status in 2 areas for antibiotic combo

05/8/2013 | American City Business Journals

The FDA granted fast-track status to Cubist Pharmaceuticals' late-stage antibiotic CXA-201, a combination of ceftolozane and tazobactam, as a treatment for hospital-acquired bacterial pneumonia and complicated urinary tract infections. The antibiotic, which already received a fast-track designation for complicated intra-abdominal infections, is in two Phase III trials for the urinary and abdominal indications. Cubist plans to initiate another late-stage trial against ventilator-associated pneumonia in the coming months.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA